Bristol-Myers Squibb Company (BMY)
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
One of the most pertinent drivers of the stock market that is often not considered by many investors is the demographic trajectory of the U.S. Currently, the U.S. population is older than ever before in history. For example, between 1980 and 2022, the median age of the American population increased from 30.0 to 38.9.
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
Bristol Myers Squibb lowered its earnings outlook earlier this year to account for recent acquisitions. One of Bristol Myers Squibb's top-selling drugs, Revlimid, has already lost patent-protected market exclusivity.
Bristol-Myers Squibb Earnings Reinforces Our Thesis
Bristol-Myers Squibb Company stock crossed $50/share after strong earnings. The company saw 18% YoY revenue growth in 2Q 2024. Bristol-Myers has a strong pipeline with potential for future growth, focusing on debt reduction and shareholder returns.
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.
Pharma Giant's Shares Up After Impressive Q2 Earnings Release
Bristol-Myers Squibb NYSE: BMY is in the healthcare sector and is the 10th largest pharmaceutical firm in the world by market capitalization. The company released Q2 2024 financial results on July 26, 2024.
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.
This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
6 Blue Chip Dividend Stock Bargains to Buy Now That All Yield 5% and More
24/7 Wall St. Insights Dividend stocks will outperform when the Federal Reserve starts to lower rates in September.
Bristol Myers Squibb Shows Resilience Amid Patent Expiry Challenges (Rating Upgrade)
Bristol Myers Squibb's Q2 2024 revenue increased 9% year-over-year, reaching $12.2 billion. Newer drugs like Reblozyl and Opdualag demonstrated strong revenue growth in Q2, 2024. Despite facing patent cliffs, BMS's up-and-coming assets like Reblozyl, Breyanzi, and KarXT for schizophrenia offer promising future revenue potential.
2 High-Yield Dividend Stocks That Could Shine in 2025
Dividend yields have historically been a strong predictor of stock returns over long periods. Current market conditions could be ripe for a rally in high-yield equities.
